Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q18388936> ?p ?o }
Showing triples 1 to 34 of
34
with 100 triples per page.
- Q18388936 subject Q8390824.
- Q18388936 subject Q8636850.
- Q18388936 abstract "EMA401 is a new drug under development for the treatment of peripheral neuropathic pain. It was recently established as a potential drug option for patients suffering pain caused by postherpetic neuralgia. It may also be useful for treating various types of chronic neuropathic pains caused by lesions and other diseases affecting the somatosensory system in addition to postherpetic neuralgia. EMA401 has been implicated in alleviating pains associated with a host of neural abnormalities, ranging from excessive nerve sprouting due to damaged nerve caused by shingles, diabetes, osteoarthritis, HIV and chemotherapy. EMA401 is a competitive antagonist of angiotensin II type 2 receptor (AT2R) being developed by the Australian biotechnology company Spinifex Pharmaceuticals. It is the S-enantiomer form of the racemate drug EMA400. Analgesic treatments currently available for pain disorders are unsuited for severe chronic neuropathic pains. EMA401 is more effective and has virtually no central nervous system side effects in comparison to current drugs for pain relief, such as Neurotin and Lyrica. Pain pathways of the other functional systems have major molecular and mechanistic differences compared to pain pathways of the peripheral nervous system. EMA401 target proteins, angiotensin II type 2 receptors, are extremely important for nociception within the peripheral nervous system and less so for nociception within other functional systems. EMA401 is the first drug on the market that targets angiotensin II type 2 receptors (AT2R) with high affinity but has a low affinity for angiotensin II type 1 receptors. Angiotensin II receptor antagonists that have existed in the pharmaceutical market have had higher affinities for angiotensin II type 1 receptors (AT1R) over type 2 receptors. AT1R are not involved with nociception. AT1R antagonists have been mostly used for the treatment of hypertension.".
- Q18388936 bioavailability "33.0".
- Q18388936 thumbnail EMA401.svg?width=300.
- Q18388936 wikiPageExternalLink chronic-constriction-injury.
- Q18388936 wikiPageExternalLink EMA401-DEVELOPMENT.html.
- Q18388936 wikiPageExternalLink TrialReview.aspx?id=347597.
- Q18388936 wikiPageExternalLink paintypes.
- Q18388936 wikiPageWikiLink Q14859647.
- Q18388936 wikiPageWikiLink Q14908164.
- Q18388936 wikiPageWikiLink Q169953.
- Q18388936 wikiPageWikiLink Q1714245.
- Q18388936 wikiPageWikiLink Q173235.
- Q18388936 wikiPageWikiLink Q2734305.
- Q18388936 wikiPageWikiLink Q328835.
- Q18388936 wikiPageWikiLink Q467717.
- Q18388936 wikiPageWikiLink Q47273.
- Q18388936 wikiPageWikiLink Q7825858.
- Q18388936 wikiPageWikiLink Q7969801.
- Q18388936 wikiPageWikiLink Q81938.
- Q18388936 wikiPageWikiLink Q8390824.
- Q18388936 wikiPageWikiLink Q8636850.
- Q18388936 wikiPageWikiLink Q912894.
- Q18388936 wikiPageWikiLink Q944828.
- Q18388936 bioavailability "33.0".
- Q18388936 type ChemicalSubstance.
- Q18388936 type Drug.
- Q18388936 type ChemicalObject.
- Q18388936 type Thing.
- Q18388936 type Q8386.
- Q18388936 comment "EMA401 is a new drug under development for the treatment of peripheral neuropathic pain. It was recently established as a potential drug option for patients suffering pain caused by postherpetic neuralgia. It may also be useful for treating various types of chronic neuropathic pains caused by lesions and other diseases affecting the somatosensory system in addition to postherpetic neuralgia.".
- Q18388936 label "EMA401".
- Q18388936 depiction EMA401.svg.